Tibolone (Livial): The Definitive Guide

What is tibolone, and how does it differ from other HRT?

Tibolone is a prescription hormonal treatment with estrogenic, progestogenic and androgenic effects after metabolism. Livial contains 2.5 mg tibolone in an oral tablet. In the reviewed UK label it treats estrogen-deficiency symptoms more than one year after natural menopause. It also has a restricted osteoporosis-prevention indication for postmenopausal women at high fracture risk who cannot use other approved prevention medicines. It is not a nonhormonal hot-flash medicine. [1], [2]

Its metabolites have different receptor activities. Two hydroxylated metabolites have estrogen-like effects; the delta-4 metabolite has progestogenic and androgenic effects. That profile makes tibolone a distinct treatment, rather than a simple tablet containing estradiol plus progesterone or a replacement for a woman’s testosterone regimen. Milligrams cannot be converted into those other hormones by arithmetic. [1]

The ordinary Livial routine is one tablet every day. The label explicitly says a separate progestogen should not be added. This product-specific instruction belongs beside its own endometrial warnings; it is not a rule that any systemic estrogen can be used without protection. Tibolone can be considered after suitability review, but past breast cancer, clot/stroke history, unexplained bleeding and other contraindications can exclude use. [1]

Natural menopause timing matters. Livial should start at least twelve months after the last natural bleed; surgical menopause has a different start instruction. A forum discussion about perimenopause or a medically induced menopause is not equivalent to the natural-menopause label. Confirm the actual population and plan with the clinician rather than treating all absent periods as the same event. [1], [2], [5]

Which daily schedule and start date apply?

The ordinary labeled pattern is continuous daily Livial with no scheduled break and no separate progestogen. Starting after natural menopause differs from surgical menopause. When changing from sequential HRT, Livial begins the day after the prior regimen is completed; from continuous combined HRT, it may begin at any time. Investigate irregular/unscheduled bleeding before starting. The label also describes immediate initiation in a GnRH-analogue context, which does not turn ordinary natural perimenopause into an equivalent indication. [1]

Which benefits can be considered?

The treatment goal for symptoms is relief of menopausal complaints that affect quality of life. The label describes improvement during the first few weeks, but that is not a guaranteed personal deadline. Assess whether hot flashes, sleep disruption or other target symptoms improve enough to justify the treatment’s risks and practical burden. A daily hormonal tablet cannot be judged solely by whether it contains familiar estrogen or progesterone names. [1], [2]

The bone indication is prevention in a selected high-risk population when other approved options are unsuitable. Bone-density improvement and fracture reduction are related but distinct outcomes. An osteoporosis treatment decision includes fracture risk and appropriate alternatives; it is not a reason to prescribe tibolone to everyone for long-term health optimization. The LIFT trial tested a lower research amount in older women with osteoporosis and also identified a stroke problem. Both benefits and harms belong in the same discussion. [1], [3]

Androgenic metabolite activity does not make tibolone an established substitute for all testosterone indications. Libido, comfort with sex and vaginal symptoms can have several determinants. Improvement in one domain does not establish treatment of hypoactive sexual desire disorder or prove that adding testosterone would be appropriate. Ask which goal remains unmet and which evidence applies to it; do not assemble a hormone combination by counting presumed activities. [1]

Some people prefer the simplicity of one continuous tablet, particularly when separate estrogen/progestogen routines were difficult. Simplicity does not erase contraindications, bleeding assessment or breast-risk uncertainty. A person who tolerated one regimen poorly may or may not tolerate tibolone better. Public experiences can suggest useful questions without predicting a response or showing that progesterone-related problems will disappear. [1], [6], [7]

Why do LIFT and LIBERATE answer different questions?

LIFT randomized 4,538 women aged 60–85 who had osteoporosis or low bone density with a vertebral fracture. They received 1.25 mg tibolone daily or placebo, with a median thirty-four months of treatment. This is a lower amount and older fracture-risk population than the standard Livial symptom regimen. Table 2 reports new vertebral-fracture rates of 10.9 versus 19.6 per 1,000 person-years, relative hazard 0.55 (95% CI 0.41–0.74). Those are rates over accumulated observation time, not percentages of all women over a fixed year. [3]

The same trial reported stroke rates of 4.3 versus 1.9 per 1,000 person-years, with 28 versus 13 events and relative hazard 2.19 (95% CI 1.14–4.23). The trial was stopped for the stroke finding. The table gives an excess rate of 2.3 per 1,000 person-years; its rounded group rates do not subtract to exactly that estimate. Do not silently replace it with a different rounded arithmetic result. A lower research amount did not eliminate serious harm in this population. [3]

LIFT also observed fewer invasive breast cancers under tibolone, but that result cannot establish safety for people with previous breast cancer. The trial excluded a breast-cancer history, and the current Livial contraindication names known, past or suspected breast cancer. The observational evidence discussed in the product label associates the standard 2.5 mg use with higher breast-cancer risk. Different populations, amounts and study methods can produce different findings; choosing only the reassuring one is misleading. [1], [3]

LIBERATE directly studied women previously treated surgically for breast cancer who had vasomotor symptoms. Of 3,148 randomized, 3,098 entered the intention-to-treat analysis: 1,556 tibolone 2.5 mg daily and 1,542 placebo. At a median 3.1 years, recurrence occurred in 237 (15.2%) versus 165 (10.7%), hazard ratio 1.40 (95% CI 1.14–1.70). These are recurrence proportions over that follow-up, not person-year rates and not estimates for people with no prior cancer. The result supports the current exclusion of prior breast cancer. [1], [4]

Endometrial results also require context. The current label describes conflicting randomized findings and observational associations with diagnosed endometrial cancer. The LIFT study’s older participants with a uterus were not screened for endometrial abnormalities at baseline; the label reports four cancers in the treated uterine subgroup and none in placebo. A product-specific instruction not to add a progestogen does not establish zero endometrial risk. [1], [3]

These studies answer particular questions, not whether tibolone is the best option for every person entering menopause. Symptom efficacy, fracture prevention, breast-cancer recurrence and stroke are different outcomes. Population, amount, duration and comparator remain attached to each result. Research at 1.25 mg is not permission to split a 2.5 mg pack or assume half the amount halves every risk. [1], [3], [4]

Which risks and restrictions need particular attention?

Do not use Livial with known, past or suspected breast cancer, estrogen-dependent malignancy, unexplained genital bleeding, untreated endometrial hyperplasia, previous/current venous clots, a known thrombophilic disorder, any history of arterial thromboembolic disease, active liver disease or persistent abnormal liver function after prior disease, porphyria, pregnancy/lactation or hypersensitivity. These are product contraindications rather than a list of minor side effects. [1]

Stroke deserves attention, especially above sixty because baseline risk rises with age. LIFT’s excess in older women does not quantify every younger person’s risk, but it cannot be ignored when choosing treatment. A history of stroke or transient ischemic attack is a contraindication. New neurological symptoms, sudden severe headache or possible clot symptoms need urgent help, rather than checking a tracker and waiting for the next review. [1]–[3]

New or persistent bleeding should be assessed. The label allows that spotting can occur early, but says to report bleeding persisting beyond six months, starting after that point or continuing after treatment stops. This does not require waiting six months with heavy, prolonged or otherwise concerning bleeding. NICE’s current HRT guidance also identifies review windows and prompt help beyond them; the exact tibolone history and clinical risk guide assessment. [1], [2], [5]

The label discusses breast and endometrial cancer with study-specific evidence, and also addresses ovarian and clot risks. A lower observational clot association than conventional HRT does not prove no clot risk. Breast changes should be reported, and screening should follow local standards and individual risk. Tibolone is not approved as prevention for breast cancer, cardiovascular disease or dementia. [1]

Warfarin and other anticoagulants require attention: Livial can enhance anticoagulant effects, including when starting or stopping. Enzyme-inducing medicines such as carbamazepine or rifampicin can alter tibolone’s effect, and St John’s wort may reduce hormone effects and change bleeding. Include supplements in the review. Do not compensate for an interaction by adding tablets or another hormone. [1]

Common unwanted effects can include abdominal/pelvic discomfort, breast tenderness, vaginal discharge, bleeding and unwanted hair growth. Livial contains lactose; specific hereditary sugar-absorption disorders are addressed in the label. New jaundice, significant blood-pressure rise, migraine-type headache or a new contraindication are reasons for prompt clinician contact and possible discontinuation. [1], [2]

How do missed doses and storage work?

For Livial, take a missed tablet when remembered unless it is more than twelve hours overdue. If more than twelve hours late, skip it and take the next tablet at the usual time; do not double. Missing a tablet may increase breakthrough bleeding or spotting. This is a time-since-missed-dose instruction, not the remaining-time-to-next-dose rule used by some other medicines. [1], [2]

Store Livial below 25°C, do not refrigerate, and keep it in the original packaging with the blister in the outer carton to protect from light and moisture. The pack contains daily tablets; a twenty-eight-tablet blister is not a sequential cycle and does not imply a scheduled break between packs. Keep the expiry and actual dispensing instructions available. [1], [2]

What do public experiences help readers ask?

Selected discussions describe trying tibolone after other regimens, uncertainty about whether it will help, and residual symptoms despite some improvement. Other readers ask about perimenopausal use or a supposed testosterone component. These are useful prompts to explain population, metabolite activity and unmet goals. They are not evidence that a personal prescription was suitable or that tibolone is safer for a particular breast history. [6], [7]

Bring the actual routine and a few concrete outcomes to follow-up: frequency/interference of target symptoms, bleeding dates, unwanted effects and any new medicines. A report that a prior regimen was difficult helps the clinician consider alternatives; it does not establish a standard transition or justify adding hormones. Improvement and nonresponse both belong in the discussion without turning selected accounts into an expected result. [1], [6], [7]

What should be monitored?

Take a full personal and family history before starting or restarting. Examination is guided by that history and the contraindications, rather than a universal hormone panel. Review cancer, clot/stroke and liver history, unexplained bleeding, other medicines and the reason for treatment. The osteoporosis-prevention indication requires its own fracture-risk context and alternatives. [1]

During treatment, reassess whether the original symptoms improve and whether the benefit still outweighs risk. The product calls for at least annual risk/benefit appraisal and individualized check-ups; NICE gives a three-month initial review and annual reviews, earlier for ineffective treatment or adverse effects/events. A normal blood hormone value does not independently prove appropriate endometrial exposure or exclude serious disease. [1], [5]

Record the actual daily tablet, start or switch date, missed tablets, bleeding pattern and meaningful functional change. Screening and breast assessment follow current practice and individual risk. New breast changes or concerning bleeding deserve earlier review. Starting/stopping with warfarin requires attention to anticoagulation; include the pharmacist and prescriber rather than treating a tablet reminder as interaction management. [1], [2]

Bleeding assessment can include gynecologic evaluation, ultrasound and biopsy according to the findings. The symptom record should distinguish an early intermittent spot from persistent, heavy or newly recurring bleeding. The product’s six-month wording does not prevent earlier evaluation when the pattern or risk is concerning. [1], [2], [5]

What happens when treatment stops?

For a planned stop, NICE allows gradual reduction or immediate cessation of HRT; gradual reduction can limit short-term symptom recurrence but does not change the longer-term difference. The reviewed Livial label does not provide a universal tablet-cutting taper. Agree on the exact approach and continuing symptom or bone plan rather than adapting another medicine’s schedule. [1], [5]

A new contraindication or serious suspected adverse effect may require immediate discontinuation and medical assessment. Surgery or immobilization needs a separate plan; the patient leaflet describes possible interruption four to six weeks before relevant surgery and asks the clinician to determine restart. Do not delay urgent help to finish an online taper. [1], [2]

After stopping, symptoms may return and ongoing bleeding still needs investigation. Bone-protection effects do not persist indefinitely after HRT ends, so the fracture-risk plan should be revisited if that was a treatment goal. If switching to an ordinary systemic estrogen regimen with a uterus, its own endometrial-protection requirements apply; Livial’s “no separate progestogen” instruction is not transferred to the new treatment. [1], [5]

How does it compare with other options?

Tibolone differs from separate estrogen/progestogen HRT and from fixed combined products. Its metabolite activities do not translate into milligram equivalents, and the clinician should compare the actual indication, contraindications, bleeding pattern and tolerability. For an ordinary estrogen regimen with a uterus, endometrial protection generally remains part of the prescription; Livial follows its own product instruction. [1], [5]

Nonhormonal vasomotor medicines address another mechanism and bring different interactions or monitoring. Vaginal treatments may be considered for persistent local symptoms under the appropriate plan; a systemic symptom treatment does not prove every vaginal symptom has resolved. A one-tablet routine may simplify administration without providing the best balance for a person with contraindications. [1], [5]

Do not compare breast or vascular safety by mixing LIFT with LIBERATE or observational standard-dose studies. A previous cancer population, older osteoporosis population and usual symptom population are different. The study comparison should guide discussion, not manufacture a universal ranking against all modern HRT. [1], [3], [4]

Common questions

Is tibolone nonhormonal?

No. Its metabolites have estrogenic, progestogenic and androgenic activity. The unfamiliar ingredient name does not remove hormonal effects or warnings. [1] The one-tablet routine is a formulation choice, not evidence of fewer hormonal precautions. Suitability still depends on cancer, clot, stroke, liver and bleeding history. Ask what the actual treatment goal is before comparing it with another regimen. See the clinical purpose. [1]

Do I add progesterone?

The Livial label says a separate progestogen should not be added. This is specific to tibolone and does not apply to every systemic estrogen product. Endometrial warnings still apply. [1] If switching to another systemic estrogen product later, that product needs its own protection plan when a uterus is present. Do not carry the tibolone instruction forward automatically or interpret absence of scheduled progestogen as absence of endometrial risk. See the treatment comparisons. [1]

Can I start while naturally perimenopausal?

The reviewed Livial instruction is at least twelve months after the last natural bleed. Surgical menopause and GnRH-analogue contexts have separately described timing; do not transfer those to ordinary natural perimenopause. [1], [2] Bleeding history and the reason periods stopped help determine the appropriate context. The label also says irregular bleeding should be investigated before starting, so a new prescription is not a diagnostic trial for an unexplained bleeding pattern. See the product schedules. [1] [2]

Is it safe after breast cancer?

Known, past or suspected breast cancer is contraindicated. LIBERATE found more recurrence with 2.5 mg tibolone than placebo; LIFT’s different population does not overturn that result. [1], [3], [4] A lower cancer incidence in an older osteoporosis trial cannot be used as reassurance for a survivor. Population and amount must stay attached to each finding; the current product contraindication is the practical rule for the decision. See the safety precautions. [1] [3]

Does a lower dose remove stroke risk?

No such claim is supported. LIFT used 1.25 mg and found an increased stroke rate in older women with osteoporosis. Research amount is not a personalized prescribing plan. [3] Age and personal vascular history remain important, and a lower research amount is not an authorized tablet-fraction plan. Do not infer that halving an amount halves every benefit and harm. The clinician should assess the actual treatment alternatives. See the study evidence. [3]

Is bleeding harmless at first?

Spotting can occur early, but heavy, persistent or concerning bleeding still needs assessment. Keep the product’s timing rules and personal risk visible; do not assume all bleeding is an adjustment effect. [1], [2], [5] Report new bleeding after a stable period and bleeding continuing after a stop. The assessment may require gynecologic investigation rather than changing tablets alone. A symptom record is helpful, but it cannot exclude endometrial disease or determine a safe delay. See the monitoring plan. [1] [2]

What happens with a missed tablet?

Take it when remembered unless more than twelve hours overdue; then skip and resume at the normal time without doubling. This may affect bleeding. [1], [2] Keep the actual amount and missed date in the record so that a later bleeding review has the right exposure history. A twenty-eight-tablet blister does not imply off-days: ordinary Livial use continues into the next pack without a scheduled break. See the product instructions. [1] [2]

Glossary

Terms used to read the product and evidence.

Adverse event

An unwanted event during treatment; it is not automatically caused by the medicine.

Amenorrhea

Absence of menstrual periods. Secondary amenorrhea occurs after periods have previously occurred.

Bioavailability

The amount of an administered medicine reaching the circulation; formulation and route can change it.

Bioidentical

Chemically identical to a hormone the body makes; the word does not establish safety or product quality.

Biopsy

A tissue sample examined for abnormalities, unlike an ultrasound measurement of thickness.

Boxed warning

A prominent warning format used in a medicine label; removing the box does not remove every risk.

Compounding

Preparing a medicine to a prescription rather than supplying a standard approved finished product.

Continuous combined HRT

Estrogen and progestogen used continuously according to their prescriptions, without scheduled progestogen-free days.

Contraindication

A condition in which a particular product must not be used under its label.

Cycle

A repeating treatment calendar. A 28-day cycle and a calendar month have different lengths.

Daily total

All doses taken on one day added together, not the average across days without treatment.

Endometrium

The lining inside the uterus that can grow in response to estrogen.

Estrogen

A family of hormones including estradiol; systemic treatment and low-dose local treatment have different purposes.

Excipient

An ingredient other than the active medicine, such as a capsule oil or lecithin.

First-pass metabolism

Processing in the intestine and liver before an oral medicine reaches the wider circulation.

Hazard ratio

A comparative event-risk estimate across follow-up, not a fixed-duration percentage.

Hormone replacement therapy (HRT)

In this guide, hormone treatment for menopause-related needs; also called menopausal hormone therapy.

Hyperplasia

Excessive tissue growth. Endometrial hyperplasia is not the same diagnosis as endometrial cancer.

Hysterectomy

Surgery removing the uterus; removal of ovaries is a different procedure.

Intrauterine device (IUD)

A device placed inside the uterus. Protection duration in HRT can differ from contraception duration.

Metabolite

A substance produced as the body processes another substance. Some progesterone metabolites affect brain signaling.

Micronization

Making particles smaller to change their dissolution and absorption, without changing the hormone molecule.

Milligram (mg)

A unit of mass; a 100 mg capsule contains 100 milligrams of active progesterone.

Observational study

A study following treatment choices rather than randomly assigning them; confounding can affect comparisons.

Off-label

Use outside a product’s authorized indication, route or schedule; it can be guideline-supported without becoming labeled use.

Oral

Swallowed, passing through the digestive system.

Perimenopause

The transition toward menopause, when periods and hormone patterns can change.

Person-years

Accumulated observation time used for event rates.

Placebo

A comparison treatment without the tested active medicine.

Postmenopause

The stage after menopause; context and other hormonal treatments matter when identifying it.

Progestogen

The broader family of progesterone-like medicines, including progesterone and synthetic progestins.

Randomized controlled trial

A study assigning participants to groups by chance to make a treatment comparison.

Sequential HRT

A regimen giving progestogen on selected days of a repeating cycle.

Systemic

Reaching the wider body through the circulation, rather than being intended mainly for a local site.

Transdermal

Absorbed through the skin, as with an estrogen patch; evidence for progesterone cream is different.

Vaginal

Administered in the vagina; the route alone does not establish systemic exposure or uterine protection.

Vasomotor symptoms

Hot flashes and night sweats.

Withdrawal bleeding

Bleeding following removal of hormonal exposure, such as after a sequential progesterone course.

How this guide was researched

We reviewed full current Livial UK SmPC and patient information, the complete LIFT manuscript, LIBERATE’s original abstract/extracted publication text and current NICE NG23. Journal full-text access to LIBERATE was not independently established; its abstract recurrence result is corroborated by the product contraindication. Exact source access is recorded. [1]–[5]

The LIFT table retains event counts, rates and rounded-rate differences. The extracted abstract contained malformed fracture-rate decimals, so the complete table was used. Trial amount and population are not converted into a standard symptom protocol. Observational findings and randomized findings remain identified separately.

Selected public text supports reader questions only. No success percentages, private education or Academy content are inferred.

Explore the sources